RSS   Newsletter   Contact   Advertise with us
Post Online Media

uniQure names Maria E. Cantor as SVP, investor relations

uniQureuniQure N.V., a human gene therapy company, announced the appointment of Maria E. Cantor as senior vice president, investor relations and communications.

Ms. Cantor joins the Company from ARIAD Pharmaceuticals, Inc. where she most recently held the role of Senior Vice President, Corporate Affairs. At ARIAD Pharmaceuticals, Ms. Cantor was a member of the senior management team and had been responsible for investor relations and corporate communications for the company since 2008.

She played an active role in several successful financing rounds for ARIAD and led the communications program for the clinical development, regulatory approval and product launch of the company’s first cancer therapeutic Iclusig (ponatinib) approved in both the U.S. and Europe.

Prior to joining ARIAD, she held the position of Senior Director, Corporate Communications at Genzyme, where she was involved in all aspects of corporate and product communications from 2001 to 2008.

In addition to her extensive expertise as a communicator for leading biotechnology companies, Ms. Cantor also held senior communications positions within the healthcare industry including Director, Marketing and Public Relations at the St. Elizabeth Medical Center in Boston, and as Director, Marketing and Communications at Optima Healthcare Inc. in Manchester, New Hampshire.

Ms. Cantor holds a Master of Science in Communications Management from Syracuse University, S.I. Newhouse School of Public Communications in Syracuse, New York and a Bachelor of Science in Mass Communication/Broadcast Journalism from Emerson College in Boston. Ms. Cantor will serve as a member of the Company’s senior management team.


 LATEST MOVES FROM the Netherlands 


 
 

We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy